Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sublingual immunotherapy.

Robert E Esch1

  • 1Research and Development, Greer Laboratories, Lenoir, NC 28645, USA. esch@greerlabs.com

Current Opinion in Otolaryngology & Head and Neck Surgery
|May 14, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized Phase IIa Trial of Purified Candida Antigen for Common Warts: Evaluating the Safety and Efficacy Across Multiple Dosing Regimens.

Dermatology and therapy·2025
Same author

The Clinical Relevance of Pollen Versus Fungal Spores in Allergic Diseases.

The journal of allergy and clinical immunology. In practice·2021
Same author

Reply.

The Journal of allergy and clinical immunology·2019
Same author

Understanding differences in allergen immunotherapy products and practices in North America and Europe.

The Journal of allergy and clinical immunology·2019
Same author

Fungal raw materials used to produce allergen extracts.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2017
Same author

Mite allergen extracts and clinical practice.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2017
Same journal

Advances in patient-specific 3D-printed models in temporal bone surgery.

Current opinion in otolaryngology & head and neck surgery·2026
Same journal

Graduated autonomy in head and neck microvascular surgery fellowship training: oncologic and reconstructive competency, safety, and educational implications.

Current opinion in otolaryngology & head and neck surgery·2026
Same journal

Costs and system-wide considerations within head and neck reconstruction: moving toward a value-based care framework.

Current opinion in otolaryngology & head and neck surgery·2026
Same journal

Modern methods of dorsal augmentation rhinoplasty.

Current opinion in otolaryngology & head and neck surgery·2026
Same journal

Flap selection for circumferential pharyngeal reconstruction.

Current opinion in otolaryngology & head and neck surgery·2026
Same journal

Improving facial scar outcomes: an evidence-based update.

Current opinion in otolaryngology & head and neck surgery·2026
See all related articles

Sublingual immunotherapy (SLIT) shows growing evidence for safety and efficacy in treating allergic rhinitis. Acceptance in the US requires addressing regulatory and evidence-based criteria for SLIT products.

Area of Science:

  • Allergy and Immunology
  • Immunotherapy
  • Respiratory Medicine

Background:

  • Sublingual immunotherapy (SLIT) is an established allergic rhinitis treatment in Europe.
  • SLIT is gaining attention in the US as an alternative to subcutaneous immunotherapy.
  • SLIT is considered investigational in the United States.

Purpose of the Study:

  • To review the accumulating evidence for sublingual immunotherapy.
  • To assess the safety and efficacy of SLIT for allergic rhinitis and potentially asthma.
  • To explore the future of SLIT in the United States.

Main Methods:

  • Review of accumulating evidence on sublingual immunotherapy.
  • Comparison of immunological effects and mechanisms with subcutaneous immunotherapy.

Related Experiment Videos

  • Evaluation of controlled studies for expanded indications.

    • Main Results:

    • Evidence for SLIT safety and efficacy is increasing.
    • Immunological effects of SLIT are similar to subcutaneous immunotherapy, with potentially different mechanisms.
    • SLIT may offer advantages for selected patients and is being studied for asthma, dermatitis, and food allergies.

    Conclusions:

    • Data support SLIT as a valid first-line treatment for allergic rhinitis.
    • US acceptance is limited by a lack of US-licensed product data and reluctance to accept European evidence.
    • Future US adoption necessitates addressing regulatory, economic, and medical factors.